volume 6, issue 1, P37-44 2013
DOI: 10.15283/ijsc.2013.6.1.37
View full text
|
|
Share

Abstract: This phase I study demonstrates that intramuscular hUCB-MSC injection is a safe and well tolerated treatment for patients with end-stage CLI due to ASO and TAO.